Breaking News

Forge Biologics Chosen as AAV Manufacturing Partner for CIRM

Aims to help advance the manufacturing of adeno-associated adenovirus (AAV) gene therapy programs from California.

Forge Biologics, a manufacturer of genetic medicines, joined forces with the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to help advance the manufacturing of adeno-associated adenovirus (AAV) gene therapy programs from California. With $5.5 billion in funding from the state, CIRM is involved in the development and funding of regenerative medicine clinical trials focused on cell and gene therapies. Forge joins the CIRM Industry Resource Partner ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters